Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Q32 Bio Inc. (QTTB : NSDQ)

• Company Description    Q32 Bio Inc. is a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis. Q32 Bio Inc., formerly known as Homology Medicines Inc., is based in WALTHAM, Mass. Number of Employees: 24

• Price / Volume Information    Yesterday's Closing Price: $11.69 Daily Weekly Monthly 20 Day Moving Average: 380,674 shares Shares Outstanding: 29.77 (millions) Market Capitalization: $348.01 (millions) Beta: 0.21 52 Week High: $23.57 52 Week Low: $1.69 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -24.14% -23.60% 12 Week -8.31% -10.25% Year To Date 252.11% 214.11%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 830 WINTER STREET - WALTHAM,MA 02451 USA ph: 781-999-0232 fax: - q32bio@argotpartners.com http://www.q32bio.com

• General Corporate Information    Officers Jodie Morrison - Chief Executive Officer and Director Lee Kalowski - Chief Financial Officer and President David Grayzel - Director Diyong Xu - Director Isaac Manke - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 746964105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/12/26 Share - Related Items Shares Outstanding: 29.77 Most Recent Split Date: 3.00 (0.06:1) Beta: 0.21 Market Capitalization: $348.01 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.36 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.54 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: 5.65 PEG Ratio: - Price Ratios Price/Book: 2.62 Price/Cash Flow: 7.71 Price / Sales: - EPS Growth vs. Year Ago Period: 43.59% vs. Previous Quarter: 18.52% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - 50.17 03/31/26 - 149.23 12/31/25 - 988.60 ROA 06/30/26 - 29.49 03/31/26 - 34.50 12/31/25 - 27.32 Current Ratio 06/30/26 - 20.30 03/31/26 - 5.36 12/31/25 - 4.85 Quick Ratio 06/30/26 - 20.30 03/31/26 - 5.36 12/31/25 - 4.85 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - 62.87 03/31/26 - 61.86 12/31/25 - 55.49 Book Value 06/30/26 - 4.46 03/31/26 - 2.96 12/31/25 - 3.41 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - 0.00 03/31/26 - 0.04 12/31/25 - 0.08 Debt-to-Capital 06/30/26 - 0.00 03/31/26 - 4.02 12/31/25 - 7.64

Powered by Zacks Investment Research ©